Pricing Log in Create free account
Friday 6 November 2026 Export BLLN’s income statement to Excel — free account

BillionToOne, Inc.

BLLN Healthcare Diagnostics & Research

BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.

Revenue
+47.2%
EPS
+164.3%
Free cash flow
+9.25%
Total debt
+60.6%

Quarter to September 2026, against a year earlier

111.96 1.93 −1.69%
Market cap
$5.3B
P/E
88.7×
Fwd P/E
146×
Dividend yield
—
F-score
n/a
Altman Z
6.04
Beneish M
−2.03
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

BillionToOne, Inc. (BLLN) Revenue

Alert me on Revenue

BillionToOne, Inc.'s revenue for fiscal 2025 was $305.1M, up 100.0% from $152.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $436.9M. BillionToOne, Inc. ranks 26th of 47 Diagnostics & Research companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $305.1M 99.97%
FY2024 $152.6M 112.72%
FY2023 $71.7M —

Quarterly newest first

Period Revenue Change
Sep 2026 $123.0M 12.36%
Jun 2026 $109.4M 0.98%
Mar 2026 $108.4M 12.84%
Dec 2025 $96.1M 15.00%
4 more quarters

Revenue against peers

Company Revenue
RDNT RadNet, Inc. compare $2.3B
QGEN QIAGEN N.V. compare $2.1B
SHC Sotera Health Company compare $1.2B
NEO NeoGenomics, Inc. compare $787.8M
VCYT Veracyte, Inc. compare $581.8M
CDNA CareDx, Inc. compare $497.4M
BLLN BillionToOne, Inc. $436.9M
ADPT Adaptive Biotechnologies Corporation compare $298.0M
GRAL GRAIL, Inc. compare $166.6M

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on BLLN